Regulatory FDA delays verdict on Beren’s rare disease drug by three months BioSpaceBeren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17.Rare DiseaseRead full story pharminent May 29, 2026 (Last updated: May 30, 2026) BioSpace Beren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s InnoventNext: Replimune gives cancer immunotherapy a third try after FDA leadership shakeup Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
